Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents

作者：Marco Gabriele Raddi, Sara Bencini, Benedetta Peruzzi, Giorgio Mattiuz, Sven De Pourcq, Michele Tanturli, Nicolas Chapuis, Angela Consagra, Luca Rigodanza, Cristina Amato, Alessandro Sanna, Elena Tofacchi, Enrico Attardi, Sophie Park, Olivier Kosmider, Francesco Annunziato, Michaëla Fontenay, Valeria Santini · 发表于：Blood Cancer Journal · 年份：2024 · DOI：10.1038/s41408-024-01112-9 · 被引用次数：7 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Hematological disorders and diagnostics

Anemia in low-risk myelodysplastic neoplasms (LR-MDS) derives from defective maturation and apoptosis of erythroid precursors [ 1 ] and its first-line (1L) treatment relies on erythropoiesis stimulating agents (ESAs) in case of serum EPO < 200 U/L. Still, 30–40% of patients selected with a high probability of response are resistant [ 2 ]. The knowledge of MDS mutational landscape has paved the way for molecular classification (WHO 2022 [ 3 ], ICC [ 4 ]) and IPSS-M prognostic risk stratification [ 5 ], but their role in ESA response has not been completely elucidated.